International Journal of Cardiology
Volume 79, Issue 2 , Pages 287-291 , July 2001

Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation

Received 27 October 2000 ,Revised 3 April 2001 ,Accepted 10 April 2001.

References 

  1. David MC, Vance JP, Andrew EE, Neal K. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 1997;30:1039–1045
  2. Arboix A, Garsia-Eroles L, Massons JB, Oliveres M, Pugades R, Tauga C. Atrial fibrillation and stroke: clinical presentation of cardioembolic versus atherothrombotic infarction. Int J Cardiol. 2000;73:33–42
  3. Dell’Orfano JT, Patel H, Wolbrette DL, Luck JC, Naccarelli GV. Acute treatment of atrial fibrillation: spontaneous conversion rates and cost of care. Am J Cardiol. 1999;83:788–790
  4. Platia EV, Michelson EL, Perterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 1989;63:925–929
  5. Ellenbogen KA, Dias VC, Cardello FP, et al.  Safety and efficacy of intravenous diltiazem in atrial fibrillation or atrial flutter. Am J Cardiol. 1995;75:45–49
  6. Bohm M, Schwinger RHG, Erdmann E. Cardiodepressant potency of various calcium channel antagonists in human myocardium. Am J Cardiol. 1990;66:1039–1041
  7. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med. 1987;106:503–506
  8. Rawles JM, Metcalfe M, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J. 1990;63:225–227
  9. DiCarlo LA, Morady F, DeBuitleir M, Krol RB, Schurig L, Annesley TM. Effects of magnesium sulfate on cardiac conduction and refractoriness in humans. J Am Coll Cardiol. 1986;7:1356–1362
  10. Rasmussen HS, Thomsen PEB. The electrophysiological effects of intravenous magnesium on human sinus node, atrioventricular node, atrium, and ventricle. Clin Cardiol. 1989;12:85–90
  11. Moran JL, Gallagher J, Peake SL, Cunningham DN, Salagaras M, Leppard P. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. Crit Care Med. 1995;23:1816–1824
  12. Gullestad L, Birkeland K, Molstad P, Hoyer MM, Vanberf P, Kjekshus J. The effect of magnesium versus verapamil on supraventricular arrhythmias. Clin Cardiol. 1993;16:429–434
  13. Brodsky MA, Orlov MV, Capparelli EV, et al.  Magnesium therapy in new-onset atrial fibrillation. Am J Cardiol. 1994;73:1227–1229
  14. Hays JV, Gilman JK, Rubal BJ. Effect of magnesium sulfate on ventricular rate control in atrial fibrillation. Ann Emerg Med. 1994;24:61–64
  15. Danias PG, Caulfield TA, Weigner MJ, Silverman DI, Manning WJ. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol. 1998;31:588–592
  16. Wesley RC, Haines DE, Lerman BB, DiMarco JP, Crampton RS. Effect of intravenous magnesium sulfate on supraventricular tachycardia. Am J Cardiol. 1989;63:1129–1131

☆ Presented in part at ‘Cardiostim 2000’, Nice Acropolis, French Riviera, 14–17 June 2000.

PII: S0167-5273(01)00450-8

International Journal of Cardiology
Volume 79, Issue 2 , Pages 287-291 , July 2001

Article Tools

* Image Usage & Resolution